| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Product revenue, net | 521 | - | 2,441 | 2,400 |
| Cost of goods sold | 479 | - | 848 | 808 |
| Gross profit | 42 | - | 1,593 | 1,592 |
| Sales and marketing | - | - | 947 | 1,019 |
| Research and development | - | - | 4 | 9 |
| General and administrative | 1,211 | 1,891 | 1,703 | 1,617 |
| Impairment of long-lived assets | 87 | 0 | - | - |
| Total operating expenses | 1,298 | 1,891 | 2,654 | 2,645 |
| Operating loss | -1,256 | -1,891 | -1,061 | -1,053 |
| Non-cash gain on changes in fair value of warrant liabilities | 0 | 0 | - | 80 |
| Non-cash loss on change in fair value of embedded derivative liability | 0 | 0 | - | 83 |
| Accretion of interest and amortization of discounts on convertible notes | 0 | 0 | 138 | 300 |
| Extinguishment of secured convertible notes | 0 | - | -13 | - |
| Other expense, net | -77 | -73 | - | -69 |
| Net loss from continuing operations | -1,333 | -1,964 | -1,212 | -1,585 |
| Net income from discontinued operations, net of taxes (notes 14, 15 and 16) | 40 | 42 | - | - |
| Net (loss) income | -1,293 | -1,922 | -1,212 | -1,585 |
| Less increase to accumulated deficit due to adjustment to common stock warrant exercise price | 0 | - | 1,005 | - |
| Less increase to accumulated deficit due to adjustment to preferred stock conversion price | 0 | 0 | - | - |
| Net (loss) income attributable to common stockholders | -1,293 | -1,922 | -2,217 | -1,585 |
| Basic (and diluted for net loss) (in shares) | 5,876,000 | 5,818,000 | 3,710,000 | 1,155,000 |
| Diluted earnings (loss) per share attributable to common stockholders (in shares) | 5,876,000 | 5,818,000 | - | - |
| Us-gaap_earningspersharebasic | -0.22 | -0.33 | -0.6 | -1.37 |
| Us-gaap_earningspersharediluted | -0.22 | -0.33 | - | - |
NovaBay Pharmaceuticals, Inc. (NBY)
NovaBay Pharmaceuticals, Inc. (NBY)